Helix BioPharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Helix BioPharma şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-13.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-13.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Is Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?

Mar 07

Auditors Have Doubts About Helix BioPharma (TSE:HBP)

Nov 03

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: HBP şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: HBP şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Helix BioPharma Piyasaya Karşı Temettü Getirisi

HBP temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (HBP)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (HBP) (3 yıla kadar)	n/a

Önemli Temettü: HBP şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, HBP şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: HBP şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: HBP herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Helix BioPharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New minor risk - Share price stability

New major risk - Negative shareholders equity

Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding

Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding

Helix BioPharma Corp. Appoints Praveen Varshney as Chief Financial Officer

Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024

New major risk - Negative shareholders equity

Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding

Helix BioPharma Corp. Announces Executive Changes

Is Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Helix BioPharma Corp. Announces CEO Changes

Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023

High number of new and inexperienced directors

Helix BioPharma Corp. announced that it has received CAD 4.62902 million in funding

Auditors Have Doubts About Helix BioPharma (TSE:HBP)

Helix BioPharma Corp. Appoints Frank Gary Renshaw as Chief Medical Officer

Helix BioPharma Corp. Appoints Gabrielle M Siegers as Head of Research Development Based Out of its Lab in Edmonton

High number of new and inexperienced directors

Helix BioPharma Corp. Appoints Namrata Malhotra as Corporate Secretary

Helix BioPharma Corp. Appoints Hatem Kawar as Chief Financial Officer

High number of new and inexperienced directors

Helix BioPharma Corp. announced that it has received CAD 2.002 million in funding

Helix Biopharma Corp. Announces Board Changes

Helix BioPharma Corp. announced that it expects to receive CAD 2.002 million in funding

Helix Biopharma Corp. Announces Resignation of Krzysztof Saczek from the Board of Directors

Helix BioPharma Corp. Appoints Adam Uszpolewicz to its Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Helix BioPharma Corp. announced that it expects to receive CAD 10 million in funding from The Lind Partners, LLC

Helix Biopharma Corp. Appoints Dr. Frank Gary Renshaw to the Scientific Advisory Board

New 90-day high: CA$1.01

Helix BioPharma Corp. announced that it has received CAD 3 million in funding

New 90-day high: CA$0.42

CAIAC Fund Management AG completed the acquisition of 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP).

Helix BioPharma Corp. announced that it has received CAD 1.1 million in funding

New 90-day low: CA$0.29

Helix BioPharma Corp., Annual General Meeting, Jan 28, 2021

New 90-day low: CA$0.30

CAIAC Fund Management AG entered into a non-binding term sheet to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) for PLN 6.7 million.

New 90-day low: CA$0.41

New 90-day low - CA$0.47

Biotech Opportunity Fund managed by CAIAC Fund Management AG acquired 19.8% stake in Helix BioPharma Corp. (TSX:HBP) for CAD 13.2 million.

New 90-day low - CA$0.51

A third-party purchaser acquired 15.5% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp.

Helix BioPharma Corp. to Report Q3, 2020 Results on Jul 30, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin